A video-based educational pilot for basal cell carcinoma (BCC) treatment: A randomized controlled trial

Love, Elyse; Manalo, Iviensan F.; Chen, Shuo; Chen, Kuang-Ho; Stoff, Benjamin K.

doi:10.1016/j.jaad.2015.10.014

Cited by 24 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In keeping with the recommendations provided by the ODPHP, our study results indicate that a brief, captioned video scripted at an elementary school level can be an effective method for patient instruction. These findings are consistent with prior work that has shown a benefit to video-based delivery ( Love et al, 2016 , Roman et al, 2016 , Van Acker and Kuriata, 2014 ).…”

Section: Discussionsupporting

confidence: 92%

“…However, this gap is less surprising when we consider that 90% of Americans have limited health literacy skills ( America’s Health Literacy: Why We Need Accessible Health Information, 2008 ). Audiovisual presentation of salient health information has been proposed as an effective method to bridge this gap because electronic media are already entrenched in modern society ( Armstrong et al, 2010 , Love et al, 2016 ). In this study, we evaluated the effectiveness of a brief, simply worded video to teach subjects about skin lesions and skin cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Video education to improve recognition of common benign and malignant cutaneous lesions and skin cancer prevention in the public

Lenczowski

Tung-Hahn

Higareda

et al. 2018

International Journal of Women's Dermatology

View full text Add to dashboard Cite

ObjectiveAlthough dermatologists strive to provide patient education on sun protection and skin cancer, approximately 90% of Americans have limited health literacy skills. Little has been written about the means to best teach all levels of learners to recognize common benign and malignant skin lesions. Earlier work found that with advancing age, adults were less able to identify concerning lesions, thus underscoring the need for accessible education.MethodsWe showed subjects a brief video (7th grade level) about common cutaneous growths, reducing the risk of skin cancer, and the importance of early detection. Subjects were asked about their skin cancer history, educational format preference, and the perceived impact of the video. Comprehension of symptoms of skin cancer and the benefits of sunscreen use and the ability to identify a melanoma, nevus, angioma, and seborrheic keratosis were also assessed.ResultsOf the 156 subjects, mean age 52.7 years (range, 18-88 years), 31% had a history of skin cancer. A total of 98.7% found the video to be helpful; 92% preferred having a video as part of their teaching versus 9% who preferred written materials alone, 99% knew that a new or changing lesion could signal skin cancer, and 100% correctly answered that wearing sunscreen is protective. Subjects correctly identified lesions as melanoma (99%), benign mole (97%), angiomas (96%), and seborrheic keratosis (91%). There was a nominal trend toward higher scores in people who preferred video learning, had no history of skin cancer, and were older than 60 years of age.ConclusionIn this study, we found that a brief, plain-language video was effective at conveying understandable content to help subjects learn to identify common cancerous and benign skin growths while also teaching them strategies to protect against skin cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Video education to improve recognition of common benign and malignant cutaneous lesions and skin cancer prevention in the public

Lenczowski

Tung-Hahn

Higareda

et al. 2018

International Journal of Women's Dermatology

View full text Add to dashboard Cite

show abstract

“…Suitably informed patients could make their own choice about the use of imiquimod and other non-surgical treatment modalities. The SINS study now provides valuable data to inform such shared decision making that might be delivered to patients by video-based educational materials (Love et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial

Williams

Bath‐Hextall

Ozolins

et al. 2017

Journal of Investigative Dermatology

119

106

View full text Add to dashboard Cite

Abbreviations BCC = basal cell carcinoma; nBCC = nodular basal cell carcinoma sBCC = superficial basal cell carcinoma; PDT = photodynamic therapy RCT = randomised controlled trial Abstract -200 words Main text -2600 words Tables -1 Figures -1 References -23 2 ABSTRACT Background: We previously reported modest clinical 3-year benefit for topical imiquimod compared with surgery for superficial or nodular basal cell carcinoma (sBCC, nBCC) at low risk sites in our non-inferiority randomised controlled SINS trial. Here we report 5-year data.Methods: Participants were randomised to imiquimod 5% cream once daily (sBCC, 6 weeks; nBCC, 12 weeks) or excisional surgery (4 mm margin). Primary outcome was clinical absence of initial failure or signs of recurrence at 3 year dermatology review. Five year success was defined as 3 year success plus absence of recurrences identified through hospital, histopathology and general practitioner records. Results:Of 501 participants randomised, 401 contributed to the modified intention-to-treat analyses at year 3 (primary outcome), 383 (96%) of whom had data at year 5. Five year success rates for imiquimod were 82·5% (170/206) compared to 97·7% (173/177) for surgery (relative risk of imiquimod success 0·84, 95% CI 0·77 to 0·91, p<0.001). These were comparable to year 3 success rates of 83·6% (178/213) and 98.4% (185/188), for imiquimod and surgery, respectively. Most imiquimod treatment failures occurred in year one. Interpretation:Although surgery is clearly superior to imiquimod, this study shows sustained benefit for lesions that respond early to topical imiquimod.

show abstract

“…In seven imiquimod treated BCC patients, complete histopathological tumor clearance was observed 6 weeks after initiation of treatments and no signs of recurrence were detected. Most importantly, systemic side effects such as myalgia, lymphadenopathy were indiscernible during the trial (Love et al, 2016). In patients with genital warts, the serum concentrations were low after daily treatment of imiquimod.…”

Section: Imiquimodmentioning

confidence: 99%

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

et al. 2017

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are a class of pattern recognition receptors that play a bridging role in innate immunity and adaptive immunity. The activated TLRs not only induce inflammatory responses, but also elicit the development of antigen specific immunity. TLR7, a member of TLR family, is an intracellular receptor expressed on the membrane of endosomes. TLR7 can be triggered not only by ssRNA during viral infections, but also by immune modifiers that share a similar structure to nucleosides. Its powerful immune stimulatory action can be potentially used in the anti-tumor therapy. This article reviewed the anti-tumor activity and mechanism of TLR7 agonists that are frequently applied in preclinical and clinical investigations, and mainly focused on small synthetic molecules, including imiquimod, resiquimod, gardiquimod, and 852A, etc.

show abstract

A video-based educational pilot for basal cell carcinoma (BCC) treatment: A randomized controlled trial

Cited by 24 publications

References 13 publications

Video education to improve recognition of common benign and malignant cutaneous lesions and skin cancer prevention in the public

Video education to improve recognition of common benign and malignant cutaneous lesions and skin cancer prevention in the public

Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

Contact Info

Product

Resources

About